Thomas Schultz, DO
Interventional Cardiology · Columbia, SCNPI 1023274776
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 300 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 300 payments — averaging $33.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Cvrx, Inc.$2K
- Medtronic$2K
- Abbott$1000
- Abiomed$904
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$472
- plus $2K from 21 others
What the payments were for
- Travel & lodging$95710%
- Food & beverage$8,94490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 52 | $2,114 |
| Cvrx, Inc. | 20 | $2,010 |
| Medtronic(2 entities) | 82 | $1,595 |
| Abbott | 17 | $1,000 |
| Abiomed | 35 | $904 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $472 |
| Novartis | 17 | $326 |
| Biotronik Inc. | 4 | $268 |
| Inari Medical, Inc. | 1 | $174 |
| Amgen | 9 | $150 |
| Cardiva Medical, Inc. | 8 | $133 |
| AstraZeneca | 8 | $107 |
| Arbor Pharmaceuticals, Inc. | 5 | $95 |
| Shockwave Medical, Inc | 5 | $94 |
| Pfizer | 4 | $69 |
| Esperion Therapeutics, Inc. | 3 | $63 |
| Philips North America LLC | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Johnson & Johnson | 3 | $46 |
| Merck | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Nuwellis, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Livanova USA, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$1,458
- AVVIGO Guidance System$499
- Impella$255
- WATCHMAN Access System$254
- Confirm Rx$233
- Perclose ProGlide suture mediated closure system$187
- FLOWTRIEVER CATHETER, S$174
- CT THROMBECTOMY SYSTEM KIT$174
- LINQ II$172
- Reveal LINQ$160
- General - Balloon Catheters$149
- Micra$134
- SUPERA$133
- GENERAL VASCULAR ACCESS$128
- Cobalt$128
How this compares
$9,901 in reported general payments places this provider in the 55th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $231,073 |
| EntrestoSacubitril/Valsartan | 120 | $160,464 |
| JardianceEmpagliflozin | 70 | $78,415 |
| XareltoRivaroxaban | 58 | $70,850 |
| Repatha SureclickEvolocumab | 75 | $59,367 |
| BrilintaTicagrelor | 55 | $36,597 |
| Metoprolol Succinate | 357 | $5,232 |
| Atorvastatin Calcium | 303 | $4,574 |
| Ranolazine ErRanolazine | 48 | $4,459 |
| Amiodarone Hcl | 79 | $2,899 |
| Rosuvastatin Calcium | 142 | $2,705 |
| Carvedilol | 253 | $2,702 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 107 | $2,012 |
| ClopidogrelClopidogrel Bisulfate | 128 | $1,834 |
| Ezetimibe | 47 | $1,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $231,073239 claims |
| NovartisEntresto | $326 | $160,464120 claims |
| Johnson & JohnsonXarelto | $46 | $70,85058 claims |
| AstraZenecaBrilinta | $107 | $36,59755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Columbia
- Michael CryerColumbia$92K
- Loren MorganColumbia$60K
- Vince VismaraColumbia$60K
- Patrick HallColumbia$50K
- George YankeyColumbia$41K
- Michael FosterColumbia$23K
- Matthew CantrellColumbia$21K
- Christopher HuffmanColumbia$21K
- Gopi ShahColumbia$16K
- Katrina BidwellColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.